RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD
33.55
+0.21 (+0.63%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close33.34
Open33.43
Bid0.00 x 0
Ask0.00 x 0
Day's Range33.41 - 33.64
52 Week Range28.74 - 35.90
Volume1,168,886
Avg. Volume1,193,332
Market Cap227.802B
Beta (3Y Monthly)0.46
PE Ratio (TTM)21.85
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.07 (3.22%)
Ex-Dividend Date2019-03-07
1y Target EstN/A
Trade prices are not sourced from all markets
  • J&J Submits BLA for Subcutaneous Formulation of Darzalex
    Zacks4 hours ago

    J&J Submits BLA for Subcutaneous Formulation of Darzalex

    Johnson & Johnson (JNJ) submits a BLA to the FDA, seeking approval for a subcutaneous formulation of its multiple myeloma drug.

  • J&J Falls Amid Reports of Criminal Probe Into Talcum Powder
    Zacks13 hours ago

    J&J Falls Amid Reports of Criminal Probe Into Talcum Powder

    The U.S. Justice Department is reportedly pursuing a criminal investigation as to whether J&J (JNJ) lied about the possible cancer risk associated with its talcum powder.

  • Amgen & Novartis' Alzheimer Studies End in Another Failure
    Zacks4 days ago

    Amgen & Novartis' Alzheimer Studies End in Another Failure

    Amgen (AMGN) and Novartis (NVS) discontinue two Alzheimer's disease studies. Alzheimer's has always been a highly challenging area with many studies failing.

  • Aimmune Down on Negative ICER Review on Allergy Candidate
    Zacks4 days ago

    Aimmune Down on Negative ICER Review on Allergy Candidate

    Aimmune's (AIMT) peanut allergy candidate AR101 attracts negative review from ICER, stating risks outweighs benefits in patients. AR101 is under review and a decision is expected by January 2020.

  • Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY
    Zacks4 days ago

    Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY

    Glaxo (GSK) provides updates on HIV regimens. FDA accepts Merck (MRK) & Sanofi's (SNY) regulatory applications for review.

  • Bristol-Myers (BMY) Down 11.6% YTD: What Lies Ahead in 2H19?
    Zacks5 days ago

    Bristol-Myers (BMY) Down 11.6% YTD: What Lies Ahead in 2H19?

    Bristol-Myers (BMY) declines on uncertainty and delay of the Celgene merger.

  • Pfizer Stock Is The Biggest Pharma — But Should You Buy It?
    Investor's Business Daily5 days ago

    Pfizer Stock Is The Biggest Pharma — But Should You Buy It?

    Pfizer stock has run sideways this year, behind pharma stocks. Recent news has been upbeat with a drug approval and earnings beat. But the question remains: Is Pfizer stock a buy right now?

  • Novo Nordisk Reports Encouraging Data From Hemophilia Studies
    Zacks7 days ago

    Novo Nordisk Reports Encouraging Data From Hemophilia Studies

    Novo Nordisk (NVO) reports data on Concizumab and Refixia for the treatment of hemophilia.

  • Roche Reveals New Hemlibra Data, Extends Spark Merger Deadline
    Zacks7 days ago

    Roche Reveals New Hemlibra Data, Extends Spark Merger Deadline

    Roche (RHHBY) presents new positive data on Hemlibra, reinforcing its efficacy and safety. Moreover, the deadline of the impending merger with Spark has been extended.

  • Benzinga7 days ago

    The Daily Biotech Pulse: Roche Presents Positive Hemlibra Data, Amgen's Tender Offer For Nuevolution Complete, Genmab Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 8) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Inspire ...

  • Reuters8 days ago

    Roche, Spark push back takeover deadline in $4.3 billion deal

    Roche and Spark Therapeutics agreed to extend the deadline for the Swiss drugmaker's $4.3 billion takeover bid for the U.S. gene therapy specialist, Roche said, adding it remains "fully committed" to a deal it sees closing this year. The new deadline for both companies to extend the merger agreement is now April 30, 2020, rather than Jan. 31, 2020, Roche said in a U.S. regulatory filing on Monday, saying the change provides "additional time to clear the transaction". Roche's March 5 bid to add Spark's gene therapy technology is dragging on, with completion pushed back several times as the Swiss company blames time-consuming U.S. Federal Trade Commission scrutiny of any competition issues.

  • Reuters8 days ago

    UPDATE 1-Roche, Spark push back takeover deadline in $4.3 bln deal

    Roche and Spark Therapeutics agreed to extend the deadline for the Swiss drugmaker's $4.3 billion takeover bid for the U.S. gene therapy specialist, Roche said, adding it remains "fully committed" to a deal it sees closing this year. The new deadline for both companies to extend the merger agreement is now April 30, 2020, rather than Jan. 31, 2020, Roche said in a U.S. regulatory filing on Monday, saying the change provides "additional time to clear the transaction". Roche's March 5 bid to add Spark's gene therapy technology is dragging on, with completion pushed back several times as the Swiss company blames time-consuming U.S. Federal Trade Commission scrutiny of any competition issues.

  • What Drove uniQure 171% Higher in the First Half of 2019
    Motley Fool8 days ago

    What Drove uniQure 171% Higher in the First Half of 2019

    Steady progress with experimental gene therapies gave investors reasons to cheer.

  • Pharma Stock Roundup: PFE's Regulatory/Pipeline Updates, CHMP Nod for Several Drugs
    Zacks11 days ago

    Pharma Stock Roundup: PFE's Regulatory/Pipeline Updates, CHMP Nod for Several Drugs

    Pfizer (PFE) provides several regulatory/pipeline updates. CHMP gives nod to several drugs.

  • Will MedTech Ease Investors' Concern & Outperform? 4 Picks
    Zacks11 days ago

    Will MedTech Ease Investors' Concern & Outperform? 4 Picks

    Lower investment in MedTech might prove to be a concern, more so as gains within this space are staggering.

  • Karyopharm Gets Accelerated FDA Approval for Myeloma Drug
    Zacks12 days ago

    Karyopharm Gets Accelerated FDA Approval for Myeloma Drug

    Karyopharm (KPTI) gets accelerated FDA approval for oral Xpovio in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.

  • Benzinga13 days ago

    FDA Places Unum's Early Stage Cancer Drug Trial On Clinical Hold

    Unum Therapeutics Inc (NASDAQ: UMRX ) shares were under pressure Wednesday following a clinical trial update provided by the company late Tuesday. What Happened The FDA has imposed a clinical hold on the ...

  • Benzinga13 days ago

    The Daily Biotech Pulse: Roche's Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance Chief

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 2) ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP ) ...

  • Puma Biotech Submits sNDA for Breast Cancer Drug Nerlynx
    Zacks14 days ago

    Puma Biotech Submits sNDA for Breast Cancer Drug Nerlynx

    Puma Biotech (PBYI) files an sNDA for the nod of Nerlynx in combination with Xeloda to treat patients with HER2-positive metastatic breast cancer, having failed two or more prior lines of treatments.

  • Alnylam Submits MAA in Europe for RNAi Therapeutic Givosiran
    Zacks14 days ago

    Alnylam Submits MAA in Europe for RNAi Therapeutic Givosiran

    Alnylam (ALNY) submits Marketing Authorization Application to the EMA for givosiran in development for the treatment of acute hepatic porphyria.

  • 13 Blue-Chip Stocks With Risks You Need to Watch
    Kiplinger14 days ago

    13 Blue-Chip Stocks With Risks You Need to Watch

    Every company faces headwinds at some point. Even the bluest of blue-chip stocks must tackle a serious threat from time to time.Dangers can come from anywhere. They can be industrial accidents such as the 2010 Deepwater Horizon oil spill that cost BP plc (BP) nearly $65 billion in legal fees, settlements and cleanup costs as of 2018. There are technological squabbles, such as Apple's (AAPL) 2017 patent infringement lawsuit settlement with Nokia, which forced the iPhone maker to pay $2 billion upfront as well as ongoing royalties from iPhone sales. Pfizer (PFE) was weighed down considerably in 2011 as it was about to lose market exclusivity on its blockbuster cholesterol drug Lipitor - this so-called patent cliff is a frequent headwind for pharma stocks.Some blue chips, such as Apple and Pfizer, take the hit and keep on chugging. Others, like BP, take much longer to recover - if they ever do.You can get some insight into potential headwinds by reading the "Risk Factors" section of each company's annual 10-K filing. Companies are required to list, by order of importance, the most significant risks challenging future profits or stock performance. Some risks apply to the entire economy, some to that particular industry and a few are unique to that company.Here are 13 blue-chip stocks that currently are navigating their way around a landmine or two. This isn't necessarily a list of stocks to sell, however. Great companies can often overcome major setbacks, and many of these companies are working toward that. But retirees need to be especially aware of forces that threaten substantial shorter-term losses. And even the most ardent bull should acknowledge and understand significant risks - even if they merely set a stock up for a dip-buying situation. SEE ALSO: 20 More Best Stocks to Buy That You Haven't Heard Of

  • Roche's Tecentriq Gets CHMP Recommendation for Breast Cancer
    Zacks15 days ago

    Roche's Tecentriq Gets CHMP Recommendation for Breast Cancer

    Roche (RHHBY) announced that its immuno-oncology drug, Tecentriq, was recommended for approval by the CHMP for triple-negative breast cancer.

  • Pfizer's (PFE) Avastin Biosimilar Zirabev Gets FDA Approval
    Zacks15 days ago

    Pfizer's (PFE) Avastin Biosimilar Zirabev Gets FDA Approval

    Pfizer (PFE) gets FDA approval for biosimilar Avastin, Zirabev. This is Pfizer's second oncology biosimilar to be approved in United States.

  • J&J's Darzalex Gets FDA Nod for First-Line Multiple Myeloma
    Zacks18 days ago

    J&J's Darzalex Gets FDA Nod for First-Line Multiple Myeloma

    Johnson & Johnson's (JNJ) label expansion application, seeking approval for Darzalex+Revlimid to treat transplant ineligible newly diagnosed patients with multiple myeloma, receives FDA approval.

  • Reuters18 days ago

    Pfizer's Avastin biosimilar wins FDA approval

    Pfizer Inc said on Friday that the U.S. Food and Drug Administration had approved its biosimilar to Roche Holding AG's blockbuster cancer treatment Avastin. Pfizer's Zirabev received approval for the treatment of five types of cancer, including colorectal and lung cancers, it said. In 2017, U.S.-based Amgen Inc's Mvasi was approved by the FDA as the first biosimilar to Roche's Avastin, which brought in revenue of $6.85 billion to the Swiss drugmaker in 2018.